Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Codex

This article was originally published in The Tan Sheet

Executive Summary

U.S. Codex office requesting comments on "Proposed Draft Working Principles for Risk Analysis" by Oct. 1. Redrafted document appears to take a step away from recognition of so-called "precautionary principle," or the application of precaution absent scientific data, within Codex itself, although it does not address the issue with regard to risk analysis guidance for governments. Document restates Codex Commission's position that when evidence of human health risk exists but scientific data are insufficient, the commission "should not proceed to elaborate a standard but should consider elaborating a related text, such as a code of practice...supported by the available scientific evidence." Redrafted document will be considered by Codex Committee on General Principles at its meeting in Paris April 15-19, 2002

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel